Savient re-evaluating prosaptide
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Savient is terminating a Phase II study of prosaptide in HIV patients with peripheral neuropathic pain, the firm says March 11. "Over the next few months," Savient will decide whether it "will pursue alternative analgesia indications, or further explore the potential of prosaptide to treat peripheral neuropathy in HIV/AIDS and other diseases." Savient said the trial was stopped due to a low probability for attaining statistical significance for the analgesia efficacy endpoint. Prosaptide reached Phase II for diabetic peripheral neuropathy, but Savient decided to focus on peripheral neuropathy associated with HIV/AIDS...